臨床婦人科産科71巻10号

2017年10月発行

今月の臨床 最新！　婦人科がん薬物療法─化学療法薬から分子標的薬・免疫療法薬まで 卵巣がん

卵巣がんにおける免疫療法（抗PD-1抗体療法）の可能性

著者： 安彦郁¹ 濱西潤三¹ 万代昌紀¹

所属機関： ¹京都大学大学院医学研究科婦人科学産科学

ページ範囲：P.935 - P.940

●近年の腫瘍免疫研究の発展により，がん微小環境における「免疫逃避機構」の存在が明らかになってきた．PD-1/PD-L1経路もその1つである．

●われわれはプラチナ耐性再発卵巣がんに対し，抗PD-1抗体ニボルマブを用いた医師主導第二相治験を行い，その有効性と安全性を報告した．

●ニボルマブを含む免疫チェックポイント阻害薬は，これまでの治療と異なる作用機序であるため，自己免疫疾患に類似した特有の副作用があることに注意が必要である．

参考文献

1）Hanahan D, et al : Hallmarks of cancer : the next generation. Cell 144 : 646─674, 2011

2）Abiko K, et al : PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res 19 : 1363─1374, 2013

3）Hamanishi J, et al : Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33 : 4015─4022, 2015

4）Topalian SL, et al : Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 : 2443─2454, 2012

5）Li K, et al : Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer : high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother 58 : 641─652, 2009

6）Liu M, et al : Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression. Mod Pathol 22 : 373─384, 2009

7）Hamanishi J, et al : The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin Immunol 141 : 338─347, 2011

8）Horikawa N, et al : Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells. Clin Cancer Res 23 : 587─599, 2017

9）Ishida Y, et al : Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11 : 3887─3895, 1992

10）Hamanishi J, et al : Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104 : 3360─3365, 2007

11）Taube JM, et al : Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4 : 127─137, 2012

12）Robert C, et al : Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 : 320─330, 2015

13）Sharma P, et al : Nivolumab monotherapy in recurrent metastatic urothelial carcinoma（CheckMate 032） : a multicenter, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 17 : 1590─1598, 2016

14）Abiko K, et al : IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer 112 : 1501─1509, 2015

15）Mandai M, et al : Dual faces of IFN γ in cancer progression : a role of PD-L1 induction in the determination of pro-and antitumor immunity. Clin Cancer Res 22 : 2329─2334, 2016

16）Peng J, et al : Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res 75 : 5034─5045, 2015

17）Okazaki T, et al : New regulatory co-receptors : inducible co-stimulator and PD-1. Curr Opin Immunol 14 : 779─782, 2002

18）Wang J, et al : Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci USA 102 : 11823─11828, 2005